Caligan Partners »

Aeglea Biotherapeutics shares owned by Caligan Partners

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Caligan Partners from 13F filings

Historical chart of Caligan Partners investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Caligan Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $44M 878k 50.44

More positions owned by Caligan Partners

Liquidia Corporation Com New (LQDA)
Revolution Medicines (RVMD)
Abivax Sa Sponsored Ads (ABVX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Mineralys Therapeutics (MLYS)
Exelixis (EXEL)
Cg Oncology Call Option (CGON)
Tango Therapeutics (TNGX)
Tyra Biosciences (TYRA)
Adma Biologics (ADMA)
Spyre Therapeutics Com New (SYRE)
Lb Pharmaceuticals Com Shs (LBRX)
Vor Biopharma Com New (VOR)
Sab Biotherapeutics Com New (SABS)

View all positions for Caligan Partners

Top funds holding Aeglea Biotherapeutics

FMR
BlackRock
Rtw Investments
Vanguard Group
Fairmount Funds Management
Perceptive Advisors
VR Adviser
Vanguard Capital Management
Driehaus Capital Management
State Street Corporation
Paradigm Biocapital Advisors
Commodore Capital
TCG Crossover Management
Tang Capital Management
Wellington Management Company

View all funds holding Aeglea Biotherapeutics